Physician profile
William Freeman
NPI 1649267667
$8,729.44
in general payments reported to CMS, 2019-2025
19 companies · $1,595 in 2025
The $1,595 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,073 · 2020: $1,300 · 2021: $2,300 · 2022: $885 · 2023: $664 · 2024: $912 · 2025: $1,595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,921 · Education: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,921.26 |
| Education | $250.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $2,892.68 | 2019-2025 | Ilumya |
| Senseonics, Incorporated | $1,816.00 | 2019-2021 | |
| Abbvie INC. | $1,168.10 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,002.07 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $565.54 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Lilly USA, LLC | $252.63 | 2019-2025 | Ebglyss, Taltz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $198.27 | 2019 | |
| Ucb, INC. | $176.17 | 2022-2025 | Bimzelx |
| Pfizer INC. | $173.20 | 2019-2025 | |
| Biofrontera INC. | $119.22 | 2019 | |
| Incyte Corporation | $91.24 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $88.42 | 2022-2024 | Sotyktu |
| Leo Pharma INC. | $57.97 | 2022-2025 | Adbry, Anzupgo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.48 | 2022 | |
| Amgen INC. | $22.93 | 2024 | Otezla |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $19.47 | 2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $18.72 | 2025 | |
| Dermavant Sciences, INC. | $14.16 | 2023 | Vtama |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.